Flemming Ornskov - Shire Plc CEO, Director

CEO

Dr. Flemming Ornskov, M.D., MBA, MPH, serves as Chief Executive Officer, Executive Director of Shire Plc. Flemming served as Chief Executive Officer Designate prior to his appointment as Chief Executive Officer on April 30, 2013. Flemming brings to his role his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He formerly held the positions of NonExecutive Chairman of Evotec AG and NonExecutive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer. From 2008 to 2010 Flemming served as Global President, Pharmaceuticals and OTC at Bausch Lomb, Inc. He also served as Chairman, and later as President and Chief Executive Officer, of LifeCycle Pharma AS from 2006 to 2008, and as President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. Earlier in his pharmaceutical career Flemming held roles of increasing responsibility at Merck Co., Inc. and Novartis AG, following a distinguished period spent in hospitals and academic medicine. Flemming received his MD from the University of Copenhagen, his MBA from INSEAD and his Master of Public Health from Harvard University. since 2013.
Age 59
Tenure 11 years
Professional MarksMBA
Phone353 1 609 6000
Webhttp://www.shire.com
Ornskov received his MD from the University of Copenhagen, MBA from INSEAD, and Master of Public Health from Harvard University.

Flemming Ornskov Latest Insider Activity

Tracking and analyzing the buying and selling activities of Flemming Ornskov against Shire Plc pink sheet is an integral part of due diligence when investing in Shire Plc. Flemming Ornskov insider activity provides valuable insight into whether Shire Plc is net buyers or sellers over its current business cycle. Note, Shire Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Shire Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Shire Plc Management Efficiency

The company has return on total asset (ROA) of 3.84 % which means that it generated a profit of $3.84 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 6.3 %, meaning that it generated $6.3 on every $100 dollars invested by stockholders. Shire Plc's management efficiency ratios could be used to measure how well Shire Plc manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 14.44 B in total debt with debt to equity ratio (D/E) of 38.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Shire Plc has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Shire Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Shire Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Shire Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Shire to invest in growth at high rates of return. When we think about Shire Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

CEO Age

Paul HubnerCanada Goose Holdings
61
Janet CarrTandy Leather Factory
62
Jonathan SchwefelVince Holding Corp
66
Cheryl HodgesPVH Corp
56
Trish DonnellyPVH Corp
52
Andrew EnglandNational CineMedia
52
Steve ShiffmanPVH Corp
59
Martijn HagmanPVH Corp
49
Brendan HoffmanVince Holding Corp
48
Thomas LesinskiNational CineMedia
64
Daniel GriederPVH Corp
56
David StefkoVince Holding Corp
67
Jon ThompsonTandy Leather Factory
52
Stefan LarssonPVH Corp
49
Fred GehringPVH Corp
59
Patricia DonnellyPVH Corp
55
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. Shire plc is a subsidiary of Takeda Pharmaceutical Company Limited. Shire plc is traded on OTC Market in USA. Shire Plc [SHPGF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Shire Plc Leadership Team

Elected by the shareholders, the Shire Plc's board of directors comprises two types of representatives: Shire Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shire. The board's role is to monitor Shire Plc's management team and ensure that shareholders' interests are well served. Shire Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shire Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sara Mathew, Non-Executive Director
Perry Sternberg, Head - U.S. Commercial
Ian Clark, Non-Executive Director
Christoph Brackmann, Interim Head of Investor Relations
William Mordan, General Counsel and Corporate Secretary
Gisele Dion, Chief Accounting Officer, Corporate Controller
Flemming Ornskov, CEO, Director
Bill Mordan, General Counsel, Company Secretary
Gail Fosler, Non-Executive Director
Philip Vickers, Head - Research and Development
David Ginsburg, Non-Executive Independent Director
Joanne Cordeiro, Chief Human Resource Officer
Jeffrey Poulton, CFO and Director
Matthew Walker, Head - Technical Operations
Ian Karp, Head of Investor Relations
Olivier Bohuon, Non-Executive Director
Susan Kilsby, Non-Executive Chairman of the Board
John Miller, Interim CFO
Andreas Busch, Executive Vice President - Head of Research and Development, Chief Scientific Officer
Howard Mayer, Senior Vice President -Head of Research and Development
Phil Vickers, Head of Research and Development
Albert Stroucken, Non-Executive Director
William Burns, Non-Executive Independent Director
Dominic Blakemore, Non-Executive Director
Oliver Strawbridge, Senior Assistant Company Secretary
Ginger Gregory, Chief Human Resource Officer
Steven Gillis, Non-Executive Independent Director
Kim Stratton, Head - International Commercial
David Kappler, Senior Independent Non-Executive Deputy Chairman of the Board
Thomas Dittrich, CFO, Executive Director
Anne Minto, Non-Executive Independent Director
Mark Enyedy, Head of Corporate Devel. and Interim General Counsel

Shire Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Shire Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Shire Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Shire Plc's short interest history, or implied volatility extrapolated from Shire Plc options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Shire Plc information on this page should be used as a complementary analysis to other Shire Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Other Consideration for investing in Shire Pink Sheet

If you are still planning to invest in Shire Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Shire Plc's history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators